DEPLETION OF IL23R EXPRESSING CELLS IN THE TREATMENT OF VARIOUS DISEASES
The present invention relates, for example, to depletion of IL23R expressing cells in the treatment of disease and, in an embodiment thereof, to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in, for example, treating inflammatory and/or autoimmune diseases and/or cancer.
The present application is a continuation-in-part of International Application No. PCT/EP2014/001282, filed May 12, 2014, which designated the U.S. and claims the benefit of priority to European Patent Application No. 13002500.0, filed May 10, 2013, each of which is hereby incorporated in its entirety including all tables, figures, and claims.
FIELD OF THE INVENTIONThe present invention relates, for example, to depletion of IL23R expressing cells in the treatment of disease and, in an embodiment thereof, to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in, for example, treating inflammatory and/or autoimmune diseases and/or cancer.
BACKGROUND OF THE INVENTIONInterleukin (IL)-23 is a heterodimeric cytokine comprised of two protein subunits, designated p40 and p19 for their approximate molecular weights. The p40 protein is shared between IL-12 and IL-23, whereas the p19 protein subunit is unique to IL-23. IL-23 signals through a two-chain receptor complex consisting of the IL-12 receptor beta-1 (IL-12Rβ1) chain, which binds to p40, and a unique IL-23 receptor chain (IL23R), which confers IL-23-specific intracellular signaling.
IL-23 induces the differentiation of naïve CD4+T cells into pathogenic IL-17-producing helper T (Th17 or Th1L-17) cells. The IL-17 secreted by this distinct helper T cell subset is an important effector cytokine during inflammation. Elevated IL-17 levels have been observed in target tissues of various autoimmune diseases and inflammatory conditions, including rheumatoid arthritis, inflammatory bowel diseases (i.e., Crohn's disease, irritable bowel disease and ulcerative colitis), and psoriasis. Therefore, IL-23 has been implicated as a critical factor in inflammatory conditions and autoimmune-mediated diseases.
Several approaches to target IL-23/IL-17 signaling have been tested so far, including antibodies directed against IL-23 or the IL-23 receptor, as potential therapeutic approaches for treating inflammatory and autoimmune diseases. With respect to the use of IL-23 as a target for potential pharmacological interventions, various neutralizing antibodies directed to the p40 subunit of IL-23 have been developed for potential use in the treatment of autoimmune driven diseases. For example, the monoclonal antibody known as “ustekinumab” (Janssen-Cilag) is an antibody that targets the common p40 subunit of IL-12 and IL-23. It has been shown to be effective in the treatment of psoriasis and psoriatic arthritis. Another monoclonal antibody that targets the smaller p19 subunit of IL-23 is described in EP 2 548 577.
With regard to strategies aimed at blocking the IL-23 receptor function by IL-23 receptor-targeting antibodies, WO 2004/042009 discloses the use of a monoclonal anti-IL-23 receptor antibody or fragments thereof (Fv, Fab, Fab′ and F(ab′)2) for the treatment of an inflammatory disease associated with elevated expression of IL-17. Moreover, WO 2008/106134 discloses the generation of humanized antibodies, which recognize the IL23R chain of the human IL-23 receptor, suitable for use in the treatment of inflammatory and autoimmune disorders. These anti-IL23R antibodies include, inter alia, antibodies conjugated to cytotoxic payloads that can be used in immunotherapy to selectively target and kill cells expressing IL23R on their surface.
A promising approach for the antibody-based treatment of various cancer diseases is the redirection of immune effector cells to specifically lyse target cells using bispecific antibodies. The bispecific antibodies recognize a particular antigen on the surface of a target cell and, simultaneously, an activating surface molecule of an immune effector cell, such as a natural killer (NK) cell or a cytotoxic T (Tc) cell, to thereby kill the target cells.
The bispecific antibody concept is, for example, used in cancer therapy where bispecific antibodies are employed that bind to a cancer antigen on cancer cells and, simultaneously, to the epsilon chain of CD3 presented on, for example, cytotoxic T cells. A well-known example of such a bispecific antibody construct is “blinatumomab”, an antibody in the BiTE (bi-specific T cell engager) format, for the treatment of non-Hodgkin's lymphoma and acute lymphoblastic leukemia. Blinatumomab was developed by Micromet and simultaneously binds to the cancer antigen CD19 as well as to CD3 on the surface of cytotoxic T cells, thereby linking these two cell types together and activating the cytotoxic T cell to lyse the target cancer cell.
The hitherto most successful antibody-based approaches to treat inflammatory and/or autoimmune diseases exploit mechanisms of action that interfere with the interaction of cytokines and their respective receptors in order to prevent signaling through cytokine receptors. Examples include inhibition of TNFα (e.g., infliximab and adalimumab), inhibition of p40 (e.g., ustekinumab) or inhibition of IL6R (e.g., tocilizumab). However, these antibodies often still allow for the signaling through redundant pathways. As a consequence, a significant number of patients cannot be effectively treated. For example, up to 40% of the patients are refractory to treatment with TNFα inhibiting antibodies.
Inhibitors of cytokines signaling cascades that are involved in the differentiation of disease-driving T cells (e.g. IL-1β, TGF-β, IL-6 and IL-23) as well as inhibitors of effector cytokines that are produced by disease-driving T cells (e.g. IFN-γ, GM-CSF, G-CSF, IL-17, TNF and IL-22) have been demonstrated to be effective in certain disease conditions. However, global elimination of individual cytokines is associated with certain disadvantages: first, it bears the risk of severe side effects as this may broadly affect immune system's ability to defend the host against pathogens. Further, redundant signaling pathways may compensate for each other. The pathogenic cell types may even become independent of certain upstream cytokines, thus leaving the patient without effective treatment.
More recently, antibodies targeting either the downstream effector cytokine interleukin-17 (IL-17) or the upstream IL-23, which drives differentiation of pathogenic IL23R expressing T cells, have proven to be safe and highly efficacious in certain autoimmune diseases. For example, the anti-IL-23 antibody ustekinumab/Stelara® showed excellent safety and efficacy in psoriasis and PsA, whereas it failed in MS and CD (Longbrake et al Expert Rev Neurother. 2009;9:319-329; Sandborn et al, Gastroenterology.2008;135:1130-1141). Similarly, anti-IL-17 therapies were efficacious in psoriasis and uveitis and to some extent in RA (Jones et al, Nature Immunology.2012;13:1022-1025); however, studies in CD with secukinumab/AIN457 were recently terminated due to lack of efficacy (Hueber et al, 2012). These results suggest that although very similar cell types are responsible for the inflammatory processes in autoimmune diseases, the cytokine pattern they produce may differ substantially between the various diseases.
By using two different IL-23-blocking antibodies in a murine experimental autoimmune encephalomyelitis (“EAE”) model for multiple sclerosis it was shown that both antibodies could completely block development of EAE symptoms in a prophylactic setting (Chen et al. J.Clin.Invest.2009;116:1317-1325). However, the blockade of IL-23 signaling appeared to be insufficient for the therapy of established MS, when the IL-23-blocking antibodies were administered during an exacerbation episode.
Instead of targeting a soluble cytokine, it is possible as well to target the corresponding cytokine receptor. For example, an antibody against IL23R was employed in a murine EAE model by administration 2 days after active immunization with an encephalitogenic PLP, and and a prophylactic activity of the anti-IL23R could be demonstrated, since the onset of EAE could be delayed and the EAE score could be reduced (Wojkowska et al., Mediators of Inflammation 2014, Article ID 590409, 1-8).
Instead of systemically blocking selected cytokines or cytokine-receptor interactions, alternative approaches aim at specifically eliminating certain immune cells. In MS, the hypothesis that elimination of immune cells can lead to long-lasting efficacy has been supported by the recent impressive clinical results with alemtuzumab/Lemtrada®. In a follow-up study to the pivotal phase 3 trial, 80% of patients did not require any further treatment for up to 24 months after the last treatment cycle. However, Lemtrada® unspecifically eliminates the major components of the adaptive immune system (all B- and T-cells) and is therefore associated with significant side-effects—such as opportunistic infections - that would not justify its broad use in other chronic inflammatory diseases.
Thus, there is still a need for new and improved treatment strategies in the treatment of various diseases, such as inflammatory and/or autoimmune diseases and cancer. In particular, bispecific molecules for use in such treatments are required that are stable, easy to produce, highly specific for a given target antigen, and have a low immunogenicity.
SUMMARY OF THE INVENTIONThe present invention meets the needs presented above by providing a bispecific construct that specifically binds to an immune effector cell, i.e. a cytotoxic effector T (Tc) cell and, simultaneously, to a IL-23 receptor expressing target cell, e.g. a pathogenic or a non-pathogenic IL-17-producing helper T cell (Th17 cell), in order to kill the IL-23 receptor expressing target cell. In a further aspect, the binding constructs herein are multivalent.
In a first aspect, the present invention provides a bispecific construct comprising at least one first binding moiety and at least one second binding moiety for use in the treatment of cancer comprising IL23R-expressing tumor cells, wherein said first binding moiety specifically binds to a first antigen present on a cytotoxic effector T (Tc) cell, and said second binding moiety specifically binds to the IL-23 receptor specific subunit (IL23R).
In a second aspect, the present invention provides a bispecific construct comprising at least one first binding moiety and at least one second binding moiety, wherein said first binding moiety specifically binds to a first antigen present on a cytotoxic effector cell, e.g., a cytotoxic effector T (Tc) cell or a cytotoxic natural killer (NK) cell, and said second binding moiety specifically binds to the IL-23 receptor specific subunit (IL23R) present on the surface of a target cell.
The present invention also provides, in further aspects, a nucleic acid or nucleic acids encoding the bispecific construct of the present invention, as well as a vector or vectors comprising said nucleic acid or nucleic acids, and a host cell or host cells comprising said vector or vectors.
Another aspect the present invention relates to a method for producing the bispecific construct of the present invention, comprising (i) providing a nucleic acid or nucleic acids according to the present invention, or a vector or vectors according to the present invention, expressing said nucleic acid or nucleic acids or said vector or vectors and collecting said bispecific construct from the expression system, or (ii) providing a host cell or host cells of the present invention, culturing said host cell or host cells, and collecting the bispecific construct from the cell culture.
Yet another aspect of the present invention relates to a pharmaceutical composition comprising the bispecific construct of the present invention and a pharmaceutically acceptable carrier.
In still another aspect, the present invention relates to the use of a bispecific construct of the present invention in the treatment of an inflammatory and/or autoimmune disease, or in a method for the treatment of an inflammatory and/or autoimmune disease, comprising administering to a subject an effective amount of the bispecific construct of the present invention. Exemplary inflammatory and/or autoimmune diseases include rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, juvenile diabetes, autoimmune uveitis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and ischemia-reperfusion injury.
In still another aspect, the present invention relates to the use of a bispecific construct of the present invention in the treatment of multiple sclerosis, in particular after the onset of an exacerbation episode, comprising administering to a subject an effective amount of the bispecific construct of the present invention.
In still another aspect, the present invention relates to the use of a bispecific construct of the present invention in the treatment of tumors whose growth, tissue invasion and/or metastasis are supported by IL23R expressing cells whereby the tumor may or may not express IL23R on its surface, comprising administering to a subject an effective amount of the bispecific construct of the present invention.
In a further aspect is a method for the treatment of a disease selected from the group consisting of: an inflammatory disease, an autoimmune disease and/or cancer, comprising, in a human patient in need thereof, depleting IL23R expressing cells.
In a further aspect is a method, wherein the patient is refractory to treatment via inhibition of IL-1β, IL-6, TGF-β, IL-23, IL-22, IL-17, IL-8, GM-CSF, G-CSF, IFN-γ and/or TNFα signaling.
In a further aspect is a method, wherein said patient has an inflammatory disease and/or an autoimmune disease and is refractory to treatment via inhibition of effector cytokine signaling of IL23R expressing cells and/or cytokine signaling that drives differentiation of IL23R expressing cells.
In a further aspect is a method, wherein the depleting comprises administering to the human patient in need thereof a bispecific construct comprising at least one first binding moiety and at least one second binding moiety, wherein said first binding moiety specifically binds to a first antigen present on a cytotoxic effector cell, and said second binding moiety specifically binds to an IL-23 receptor specific subunit (IL23R) present on the surface of a target cell, wherein said bispecific construct is administered in an effective amount for the treatment of the disease in the patient.
In a further aspect is a method, wherein the cytotoxic effector cell is selected from the group consisting of: a cytotoxic effector T (Tc) cell and a cytotoxic natural killer (NK) cells.
In a further aspect is a method, wherein said first binding moiety specifically binds to an antigen selected from CD3 and CD28.
In a further aspect is a method, wherein said first binding moiety specifically binds to an agonistic epitope of CD3ε.
In a further aspect is a method, wherein said first binding moiety and/or said second binding moiety comprises a heavy chain variable domain (VH) or binding fragment thereof and a light chain variable domain (VL) or binding fragment thereof.
In a further aspect is a method, wherein the bispecific construct is in a format selected from the group consisting of a single-chain diabody (scDb), a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a circular dimeric scDb (CD-scDb), a bispecific T-cell engager (BiTE; tandem di-scFv), a tandem tri-scFv, a tri(a)body, bispecific Fab2, di-miniantibody, tetrabody, scFv-Fc-scFv fusion, di-diabody, DVD-Ig, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, including bsAb, Bs1Ab, Bs2Ab, Bs3Ab, Ts1Ab, Ts2Ab, and Knob-into-Holes (KiHs) and DuoBodies.
In a further aspect is a method, wherein the cancer is cancer metastasis.
In a further aspect is a method, wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, breast cancer, melanoma, brain cancer, nasopharyngeal cancer, oral cancer, esophageal cancer, pancreatic cancer, kidney cancer, B-cell lymphomas, and T-cell lymphomas, including adult T-cell lymphoma leukemia (ATLL), acute myeloid lymphoma (AML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), pediatric acute lymphoblastic lymphoma (B-ALL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), T-/natural killer-cell lymphomas, and peripheral T-cell lymphoma (PTCL).
In a further aspect is a method, wherein the inflammatory and/or autoimmune disease is selected from the group consisting of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, irritable bowel disease, Crohn's disease, systemic lupus erythematosus, juvenile diabetes, autoimmune uveitis, multiple sclerosis, neuromyelitis optica/Devic's disease, Parkinson's disease, Alzheimer's disease, clinically isolated syndrome and ischemia-reperfusion injury.
In a further aspect is a method, wherein the treatment is in an amount to effective to treat recurrence of the inflammatory and/or autoimmune disease.
In a further aspect is a method, wherein the effector cytokines are IL-17, IL-22, GM-CSF, G-CSF, TNF and/or IFN-gamma.
In a further aspect is a method, wherein the cytokines that drive differentiation are IL-1 beta, TGF-beta, IL23, IFN-gamma and/or IL-6.
In a further aspect is a method, wherein the IL23R binding moiety VL is:
and the IL23R binding moiety VH is:
In a further aspect is a method, wherein the CD3 binding moiety VL is:
and the CD3 binding moiety VH is:
Particular embodiments of the present invention are set forth in the appended dependent claims and elsewhere herein.
In a first aspect, the present invention provides a bispecific construct comprising at least one first binding moiety and at least one second binding moiety for use in the treatment of cancer comprising IL23R-expressing tumor cells, wherein said first binding moiety specifically binds to a first antigen present on a cytotoxic effector cell, e.g., a cytotoxic effector T (Tc) cell or a cytotoxic natural killer (NK) cell, and said second binding moiety specifically binds to the IL-23 receptor specific subunit (IL23R).
Within the meaning of the present invention, the term “construct” refers to any chemical entity so long as it exhibits the desired binding activity. Thus, the term “construct” is used in the broadest sense and specifically covers protein-based molecules, including recombinant antibodies and fragments thereof comprising one or more antibody-based domains or binding fragments thereof. Specific examples include, but are not limited to, monoclonal chimeric antibodies, humanized antibodies, single-chain diabodies and the like. Furthermore, the term “comprise” as used within the present invention, for example in conjunction with the term “construct”, encompasses both “includes” and “consists of”. Moreover, the term “including” used herein means including but not limited to.
The term “bispecific”, as used herein, is intended to refer to a construct having two different antigen specificities and, optionally, other binding moieties that bind to their respective binding partners, such as a moiety that binds to an Fc receptor or a tag for detection and/or purification. This means that a bispecific construct is capable of simultaneously binding to at least one antigen “A” and at least one antigen “B”, wherein A and B are not the same. Thus, whilst having two different antigen specificities, a bispecific construct of the present invention does not necessarily have only two binding moieties, one for each targeted antigen, but may also include more than two binding moieties. Furthermore, the term “antigen”, as used herein, is to be interpreted in a broad sense and includes any target moiety that is bound by the binding moieties of the bispecific construct of the present invention.
As used in the present invention, the terms “specific” or “specifically” are intended to mean that the first and second binding moieties are able to discriminate between their respective target molecules (i.e. between the first and second antigen) and/or one or more reference molecule(s). Thus, in its broadest sense, “specific binding” or “specifically binding” refers to the first and second binding moieties' ability to discriminate between the first antigen on the surface of a Tc cell and the IL23R second antigen on the surface of a target cell and/or between other target molecules that are related to or not related to the first antigen and/or the second antigen (i.e., IL23R).
The binding specificity of a specific binding moiety can be determined as known in the art using, for example, surface plasmon resonance (SPR), western blot, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA or IRMA), enhanced chemiluminescence (ECL), and peptide scan analysis.
If an ELISA assay is used, the scoring can be carried out by means of a standard color development reaction, for example by using horseradish peroxidase (HRP)-conjugated second antibodies in a HRP, H202, tetramethyl benzidine system. The optical density of the color development in the reaction vessel (e.g. well) at a given wavelength is a measure of the binding specificity. A typical background signal (negative reaction) may be about 0.1 OD, whereas a typical signal for a positive reaction may be about 1.0 OD or higher, resulting in a signal to noise ratio of 10:1 or higher. Typically, the determination of the binding specificity is carried out using a set of about three to five unrelated biomolecules, such as milk powder, BSA, transferrin and the like, rather than using only a single reference biomolecule.
In particular, the present invention relates to a method for the treatment of cancer comprising IL23R-expressing tumor cells, comprising administering to a subject, for example, a mammalian subject and particularly a human patient, an effective amount of the bispecific construct of the present invention.
Further provided herein is a method for the treatment of tumors whose growth, tissue invasion and/or metastasis are supported by IL23R expressing cells whereby the tumor may or may not express IL23R on its surface, comprising administering to a subject for example a mammalian subject and in particular a human subject an effective amount of an agent that depletes such IL23 expressing cells, e.g., the bispecific construct described herein.
The term “effective amount” is defined below. Typically, an effective amount of the bispecific construct of the present invention is administered in form of the above-described pharmaceutical composition. Suitable administration routes include, but are not limited to, topical and parenteral administration, in particular subcutaneous and intravenous injection. The administration regimen is not particularly limited and includes, for example, continuous infusion over one week, two weeks or four weeks.
The cancer to be treated includes, but is not limited to, colorectal cancer, lung cancer, breast cancer, melanoma, nasopharyngeal cancer, oral cancer, esophageal cancer, pancreatic cancer, kidney cancer, B-cell lymphomas, and T-cell lymphomas, including adult T-cell lymphoma leukemia (ATLL), acute myeloid lymphoma (AML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), pediatric acute lymphoblastic lymphoma (B-ALL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), T-/natural killer-cell lymphomas, and peripheral T-cell lymphoma (PTCL). In particular embodiments the cancer is selected from colorectal cancer, lung cancer, breast cancer, melanoma, kidney cancer, nasopharyngeal cancer, oral cancer, esophageal cancer, B-cell lymphomas, and T-cell lymphomas such as adult T-cell lymphoma leukemia (ATLL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), T-/natural killer-cell lymphomas, and peripheral T-cell lymphoma (PTCL).
The balance between interleukin (IL)-23 and IL-12 plays an important role in regulating the anti-tumor immune response. IL-23 and IL-12 are heterodimeric cytokines that share one of their domains (p40). While IL-12—consisting of the two subunits p35 and p40—has been found to have antitumor effects, IL-23 that is composed of p40 and p19, seems to promote growth of certain tumors by direct effects on tumor cells and by indirect mechanisms creating a tumor supportive inflammatory microenvironement. IL-12 drives the development of IFN-y producing Th1 cells, which are crucial for the antitumor immunity (Dunn, G. P. et al. 2006. Nat. rev. Immuno1:6;836-848; Colombo, M. P. and Trinchieri, G.2002.Cytokine Growth Factor Rev;13:155-168). IL-12 and IFN-γ are able to inhibit the expansion of intratumoral T regulatory cells (Tregs) that antagonize the activity of Th1 cells, as well as angiogenesis in the tumor microenvironment, thus enhancing tumor control (Cao, X et al.2009.Cancer Res;69:8700-8709). In line with a converse effect of IL-23 in the tumor microenvironment, IL-23 suppresses IL-12-dependent IFN-γ secretion in T cells (Sieve, A. N. et al. 2010.Eur. J. Immuno1;40;2236-2247). In the gut, IL-23 produced by dendritic cells (DCs) in response to microbial products, cellular stress and cell death, may drive the formation of Th17 cells instead of an antitumor Th1 response. These Th17 cells in turn also produce IL-23, which may inhibit the immune surveillance activity mediated by cytotoxic T cells by potentially preventing their ability to infiltrate into the tumor (Ngiow, S. F.2013.Trend in Immunology;34:548-555) and to affect antitumor and antimetastatic functions of NK cells (Teng, M. W. et al. 2010PNAS;107:8328-8333). In line with the view that IL-23 signaling may have effects supporting tumor formation and/or growth in certain tumors is the finding that mice deficient only in IL-12 signaling show increased tumor growth, while mice deficient for both, IL-12 and IL-23 signaling, show no increased risk of developing tumors (Street, S. E. et al.2002. J. Exp. Med;196:129-134; Airoldi, I, et al. 2005.Blood;106:3846-3853). Furthermore, mice specifically deficient for IL-23 signaling—but not for IL-12 signaling—were found to be almost completely resistant to tumor formation and showed attenuated tumor growth (Langowski, J. L. eta1.2008. Nature;442:461-465; Teng, M. W. et al. 2010PNAS;107:8328-8333). In a recent study it was further found that the coadministration of an anti-CD40 antibody stimulating T-cells together with an anti-IL-23 antibody attenuating the Th17 response showed better efficacy as compared to either antibody alone (von Scheidt, B. et al. 2014.Cancer Res;D01:10.1158/0008-5472.CAN-13-1646), possibly by shifting the balance from Th17 to Th1. In the human situation, independent clinical studies have reported that serum concentrations of IL-23 are increased in cancer patients in comparison with healthy individuals (Li, J. et al.2012. PLoS ONE;7:e46264; Gangemi, S. et al.2012. J. Cell. Biochem; 113:2122-2125; Ljujic, B. et al.2010. Arch. Med. Res; 41:182-189; He, S. et al. 2011.Int. J. Mol. Sci;12:7424-7437; Fukuda, M, et al.2010.1nt. J. Oncol; 36:1355-1365). For example in pancreatic cancer, elevated IL-23 levels correlated with disease stage and in breast cancer with poor prognosis (He, S. et al. 2011.Int. J. Mol. Sci;12:7424-7437). In primary hepatocellular carcinoma (HCC) higher IL-23 levels in the cancer microenvironment have been associated with poor prognosis. Also in colorectal cancer serum IL-23 levels were increased in patients as compared to healthy donors (Stanilov, N. S.2009.Labmedicine;41:159-163). Further, Th17 gene expression profiles as well as Th17 cell infiltrations in colorectal cancer tissue samples were associated with drastically worse prognosis as opposed to Th1 gene expression or Th1 cell infiltration (Tosolini et al, Cancer Res 2011;71:1263-1271). Collectively, these data suggest that IL-23 promotes tumorigenesis by driving protumor inflammation to suppress antitumor effector cells.
Human IL23R is predominantly found in activated memory T cells, natural killer (NK) cells, and innate lymphoid cells (ILCs), and at lower levels on monocytes, macrophages, and dendritic cells (DCs). Recently, direct effects of interleukin IL-23 on tumor cells have been described, suggesting that IL23R is expressed also on certain tumors. For example IL-23 was shown to have pro-proliferative effects on human oral squamous cell carcinoma (SSC) cell lines (Fukuda, M et al.2010. Int. J. Onco1;36:1355-1365; Fukuda, M et al.2010. Mol. Med. Rep,;3:89-93) and non-small cell lung cancer (NSCLC) cell lines (Baird, A.M. et al.2013. Lung Cancer;79:83-90). Using genome-wide association studies, two sequence variants of IL23R have been associated with the risk of several solid cancers and the same polymorphisms have been found to predispose individuals to an increased risk of acute myeloid leukemia (AML) (Xu, Y, et al.2013.J Gastroentero1;48:125-131; Chu, H. et al.2012.1nt. J. cancer;130:1093-1097; Chen, J. et al.2010. mol. Carcinog;49:862-868; Qian, X. et al.2013. PLoS ONE;8:e55473). IL23R expression was further found to be upregulated in primary tumor tissue of small cell lung cancer (SCLC), in lung andenocarcinoma (Li, J. et al.2013. Carcinog;34:658-666), in follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) (Cocco et al.Leukemia.2012:26:1365-1374), in pediatric B-ALL (Cocco et al.Blood.2010;116:3887-3898) as well as in colorectal carcinoma (CRC) (Lan et al, Int J Colorectal Dis 2011;26:1511-1518; Suzuki et al, Oncology Letters 2012;4:199-204). In CRC a correlation between expression level and severity/metastasis was found (Carlsson et al,Br J Cancer 2012;106:517-524).
Taken together, IL-23 seems to create an inflammatory microenvironment that on one hand favors tumor formation, growth and metastasis and on the other hand supports tumor immune escape by attenuating the Th1 antitumor response (see
Here we present a novel approach aiming at optimally balancing efficacy and safety, by specifically targeting cancer cells on one hand and by locally stimulating the anti-tumor immune-response on the other hand. To achieve this, a bispecific anti-IL23RxCD3c antibody is employed that acts through the mechanisms, illustrated in
-
- a) Redirecting CD3+cytotoxic T cells to lyse IL23R expressing tumors;
- b) Stimulating CD3+Th1 and T killer cells specifically in the tumor microenvironment, as binding to target cells and consequently cross-linking of CD3c binding domains is required for T cell stimulation;
- c) Redirecting CD3+cytotoxic T cells to lyse IL23R expressing Th17 cells, thereby eliminating a major source of Th1 inhibitory cytokines;
- d) Redirecting CD3+cytotoxic T cells to lyse IL23R expressing regulatory T (Treg) cells that inhibit the Th1 anti-tumor response; and
- e) Optionally: blocking IL-23 signaling by competing with IL-23 binding to its receptor IL23R.
In particular embodiments, said human patient is a patient, which has a high Th17 response.
As shown in the examples herein, treatment with the bispecific molecule of this invention indeed drastically reduced metastasis formation in the B16F10 mouse melanoma metastasis model, showing that the IL23R expressing cell population is key not only for tumor growth but surprisingly also for tumor metastasis.
In the context of the present invention, the term “high Th17 response” refers to a situation, where a patient either shows increased Th17 gene expression or increased counts of Th17 cells. An increased Th17 gene expression may be shown by increased levels of Th17 gene mRNA in the tumor tissue when compared to normal distant control tissue. In colorectal cancer such increase is at least 2-fold, particularly 4-fold and most particularly 5- to 6-fold for the genes IL17A and RORC (see Tosolini et al., Cancer Res 2011;71:1263-1271) between tumor tissue and normal distant mucosa. An increased count of Th17 cells may be seen in the tumor tissue or in the tumor adjacent tissue compared to distant control tissue. In colorectal cancer, such increased counts are observed in the center or at the invasive margin, particularly in both the center and the invasive margin of the tumor (see Tosolini et al., loc. cit.).
IL-23R expressing cells include but are not limited to IL-23R expressing Th17 cells, IL-23R expressing gamma-delta T cells (for example, CD27-negative gamma-delta T cells), IL-23R expressing Th22 cells, IL-23R expressing Tc17 cells, IL-23R expressing leukocytes and other cells expressing IL-23R and/or responding to IL-23.
Moreover, the treatment of cancer and the inflammatory and/or autoimmune diseases described herein further includes treatment of such diseases by reducing and/or depleting IL-23R expressing αβ T cells that produce effector cytokines, such as IL-17, GM-CSF, G-CSF, IL-22, IFN-γ and TNF, in particular IL-17, IFN-γ and GM-CSF. The reduction or depletion of such cells includes sufficient cell reduction or depletion to provide the desired level of treatment. As used herein, to deplete IL-23R expressing cells refers to reducing the number of such cells in an amount effective to achieve a desired reduction in the disease, including healing, reduction of disease symptoms, complete or partial abatement or remission of the disease, and complete or partial prophylaxis.
Binding of the constructs, e.g., the bispecific molecules, described herein to both targets engages cytotoxic effector cell, e.g., a cytotoxic effector T (Tc) cell or a cytotoxic natural killer (NK) cells to lyse IL23R expressing cells, thus eliminating pathogenic disease-causing lymphocytes. This approach results in better and broader efficacy as compared to blockade of individual cytokines. Such an anti-IL23RxCD3 bi-specific antibody fragment very selectively targets a pathogenic subpopulation of activated leukocytes, the elimination of which is not expected to limit the protection afforded by the immune system as such, as a broad repertoire of naive and responsive B- and T-cells will be maintained. For example in the gamma-delta T cell compartment only a small subpopulation of CD27 negative/CD3 bright cells is expressing the typical Th17 cytokines and it is only this population that is positive for IL23R (Paget et al. Immunology and Cell Biology.2014:1-15; Chognard et al. PLOS ONE.2014;9:1-15). Besides the gamma-delta T cells it has been shown in IL23R-GFP reporter mice that IL23R expression is associated to IL-17 producing CD4+ alpha-beta T cells and certain IL-17 producing myeloid cells (Awasthi et al. J Immunol.2009;182:1-11). Due to the restricted expression of IL23R on pathogenic inflammatory cells the specific elimination of IL23R expressing pathogenic cells will be even safer than the more traditional blockade of individual cytokines (e.g. TNF) that are globally involved in immune processes, particularly because only a very small fraction of T cells is indeed expressing IL23R.
Specific elimination of the disease driving Th17 cells in MS holds the potential to show similar efficacy as alemtuzumab/Lemtrada® with better safety though. It has been demonstrated that expression of IL-23 and IL-17 is upregulated in lesions and the percentage of IL-17 expressing cells correlates with disease activity (Tzartos et al, Neurbiology.2008:172:146-155; Kebir et al, Nature medicine. 2007;13:1173-1175) and further, that Th17 but not Th1 cells are increased in the cerebrospinal fluid (CSF) of MS patients (Brucklacher-Waldert et al. Brain.2009:132;3329-2241). Further, it has been demonstrated that the Th17 cytokines IL-17 and IL-22 disrupt the blood brain barrier, which is a prerequisite for the invasion of inflammatory cells into the CNS (Kebir et al.Nature Medicine.2007;10:1173-1175). In a monkey EAE model for multiple sclerosis, the IL-23 inhibitory antibody Stelara, which interferes with differentiation and activation of Th17 cells, showed good efficacy when tested in a prophylactic setting in which differentiation of IL23R expressing cells is blocked (Brok H P M et al. J Immunol 2002;169:6554-6563). Further, preclinical animal studies suggest that the memory of the disease (EAE) lies in the Th17 compartment, indicating that specific elimination of IL23R expressing cells (in particular Th17 memory cells) could result in a long-lasting amelioration of the disease phenotype (McGeachy et al, Nat Immunol. 2009 March; 10(3): 314-324. doi:10.1038/ni.1698. and Haines et al, Cell Rep. 2013 Apr. 24. pii: S2211-1247(13)00159-9. doi: 10.1016/j.celrep.2013.03.035.). Despite the very strong scientific support for the role of IL23R expressing cells in MS, the interleukin-12/23 inhibiting antibody Stelara did not show significant responses in a phase II clinical study in MS. A probable explanation for this is the unfortunate patient inclusion criteria in this phase II study (Longbrake E and Racke M K Expert Rev Neurother. 9(3),319-321 (2009)). The enrolled patients had advanced disease, in which the so-called Th17 cells have already terminally differentiated, and terminally differentiated Th17 cells may no longer be dependent on IL-23 signaling, do however continue to express the IL-23 receptor (McGeachy M J Nat Immuno.2009;10:314-324). In contrast to Stelara, the present approach targets terminally differentiated IL23R expressing cells. Recent experiments with a mouse surrogate for the bispecific constructs in accordance with the present invention have indeed demonstrated efficacy not only in a prevention setting but surprisingly also by a therapeutic intervention starting after the onset of the acute phase of the disease when Th17 cells have already terminally differentiated. This is in sharp contrast to the lack of efficacy to block the acute exacerbation in this model of two different IL-23-blocking antibodies in the same therapeutic setting (Chen et al. J.Clin.Invest.2009;116:1317-1325). Hence, the blockade of IL-23 signaling appears to be insufficient for the therapy of established MS, while depletion of IL23R expressing cells is showing strong effects.
Thus, the treatment of the diseases described herein further includes the treatment of such diseases in a subject refractory or resistant to treatment with inhibitors of, including blockers of (e.g., antibodies against) signals leading to the differentiation of IL23R expressing cells, such as, IL-6, IL-1β, TGF-8, and/or IL-23.
In particular the treatment of the diseases described herein further includes the treatment of autoimmune diseases after the onset of an acute exacerbation. Non-limiting examples for diseases in which such acute exacerbations may occur, are multiple sclerosis, clinically isolated syndrome and neuromyelitis optica.
Further, the treatment of the diseases described herein includes the treatment of such diseases in a subject refractory or resistant to treatment with inhibitors of, including blockers of (e.g., antibodies against) signals of effector cytokines produced by IL23R expressing cells, such as IL-17, GM-CSF, G-CSF, IL-22, IFN-γ, and/or TNFα.
Additionally, the treatment of the diseases described herein further includes the treatment of such diseases in a subject refractory or resistant to treatment with conventional tumor therapies (e.g., chemotherapies), or antibodies against targets such as HER-2, HER-3, VEGF, CEA, EGFR, IGFR, FASL,
Moreover, the treatment of cancer and the inflammatory and/or autoimmune diseases described herein further includes the treatment of a subject having an advanced stage of such diseases, wherein Th17 cells and/or other IL-23R expressing cells have terminally differentiated and therefore are no longer dependent on IL-23 signaling.
Moreover, the treatment of cancer and the inflammatory and/or autoimmune diseases described herein further includes the treatment for the recurrence of such diseases in a subject. For example, the treatment steps described herein can be effective in treating a disease where local memory exists in IL-23R expressing cells. An example of such a disease is an aspect of psoriasis, in which, for example, epidermal Th22 and Tc17 cells, which both express IL23R, form a localized disease memory, even in clinically healed psoriasis. Accordingly, treatment for disease recurrence can be achieved, for example, by treatment that reduces or eliminates this local memory and therefore results in a long lasting treatment effect.
In a further aspect, the present invention relates to a bispecific construct having at least one first binding moiety and at least one second binding moiety. The first and second binding moieties specifically bind to a first antigen and a second antigen, respectively. The first antigen is an antigen present on the surface of an immune effector cell, namely a cytotoxic effector T (Tc) cell (also known as cytotoxic T lymphocyte (CTL) or T killer cell). The second antigen is the IL-23 receptor specific subunit, IL23R, present on the surface of a target cell.
Within the present invention, one target cell type is typically a pathogenic cell, in particular a pathogenic T cell, more particularly a T cell expressing the transcription factor RORγ(t). RORγ(t) promotes thymocyte differentiation into pro-inflammatory Th17 cells and also plays a role in inhibiting apoptosis of undifferentiated T cells and promoting their differentiation into Th17 cells, possibly by down-regulating the expression of the Fas ligand and IL-2, respectively. In particular embodiments, the cells are selected from the group consisting of IL-17 producing T cells (Th17 cells),
T cells, natural killer T (NKT) cells and invariant natural killer (iNK) cells. Most particularly, the target cells within the present invention are selected from Th17 cells and γδ cells.
Another target cell type within the present invention is a tumor cell, particularly a tumor cell expressing IL23R. IL23R expression has for example been shown for epithelial cancers such as colon carcinoma (CRC), small-cell lung cancer (SCLC), adenocarcinoma (AC) of the lung, as well as on various B- and T-cell tumors, exemplified by diffuse large B- cell lymphoma (DLBCL), follicular lymphoma (FL), pediatric B-ALL and acute myeloid lymphoma (AML).
In particular such embodiments, said bispecific construct has at least one first binding moiety directed against an antigen present on the surface of an immune effector cell, namely a cytotoxic effector T (Tc) cell (also known as cytotoxic T lymphocyte (CTL) or T killer cell), and at least a second binding moiety directed against the IL-23 receptor specific subunit, IL23R, present on the surface of a tumor cell, wherein said bispecific construct is also able to eliminate IL23R expressing cells, such as Th17 cells and to stimulate an anti-cancer immune response. In particular such embodiments the anti-cancer immune response is driven by CD3 expressing cells. In more particular such embodiments, said first antigen is CD3, particularly CD3ε.
The first and second binding moieties are not structurally limited so long as they specifically bind to the desired first and second antigens. However, the first and second binding moieties generally consist of or are formed of one or more oligo- or polypeptides or parts thereof. Particularly, the first and second binding moieties are antibody-based binding moieties, which typically comprise at least one antibody variable domain or binding fragment thereof.
In a particular embodiment of the present invention, the first binding moiety specifically binds to a first antigen selected from CD3 and CD28. The CD3 protein is associated with the T cell receptor (TCR) and required for T cell activation. CD3 is a complex of one CD3y, one CD38 and two CD3s chains which, together with the TCR and the -chain, form the TCR receptor complex. CD28 is one of the molecules expressed on T cells that provide co-stimulatory signals required for T cell activation. Stimulation through CD28 can provide a potent co-stimulatory signal to T cells.
In a particular embodiment of the present invention, the first binding moiety binds specifically to CD3, more particularly to the epsilon chain of CD3 (CD3s), and most particularly to an agonistic epitope of CD3e. The term “agonistic epitope”, as used herein, means (a) an epitope that, upon binding of the bispecific construct of the present invention, optionally upon binding of several bispecific constructs on the same cell, allows said bispecific constructs to activate TCR signaling and induce T cell activation, and/or (b) an epitope that is solely composed of amino acid residues of the epsilon chain of CD3 and is accessible for binding by the bispecific construct of the present invention, when presented in its natural context on Tc cells (i.e. surrounded by the TCR, the CD3γ chain, etc.), and/or (c) an epitope that, upon binding of the bispecific construct of the present invention, does not lead to stabilization of the spatial position of CD3ε relative to CD3γ.
In another particular embodiment of the present invention, instead of binding to Tc cells, the first binding moiety specifically binds to a component of the complement system, such as C1 q. C1q is a subunit of the C1 enzyme complex that activates the serum complement system.
In an alternative embodiment, the present invention also contemplates the use of a first binding moiety that specifically binds to an Fc receptor, in particular to an Fc gamma receptor (FcγR). The FcγR may be a FcyRIII present on the surface of natural killer (NK) cells or one of FcγRI, FcγRIIA, FcγRIIB1, FcγRIIB2, and FcγRIIIB present on the surface of macrophages, monocytes, neutrophils and/or dendritic cells.
In such embodiment, the first binding moiety particularly is an Fc region or functional fragment thereof. In the present context, a “functional fragment” refers to a fragment of an antibody Fc region that is still capable of binding to an FcR, in particular to an FcγR, with sufficient specificity and affinity to allow an FcγR bearing effector cell, in particular a macrophage, a monocyte, a neutrophil and/or a dendritic cell, to kill the target cell by cytotoxic lysis or phagocytosis. Particularly, a functional Fc fragment is capable of competitively inhibiting the binding of the original, full-length Fc portion to an FcR such as the activating FcyRl. Particularly, a functional Fc fragment retains at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% of its affinity to an activating FcγR.
Within such embodiment of the present invention, the Fc region or functional fragment thereof is particularly an enhanced Fc region or functional fragment thereof. The term “enhanced Fc region”, as used herein, refers to an Fc region that is modified to enhance Fc receptor-mediated effector-functions, in particular antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-mediated phagocytosis. This can be achieved as known in the art, for example by altering the Fc region in a way that leads to an increased affinity for an activating receptor (e.g. FcγRIIIA (CD16A) expressed on natural killer (NK) cells) and/or a decreased binding to an inhibitory receptor (e.g. FcγRIIB1/B2 (CD32B)).
Suitable alterations within the present invention include altering glycosylation patterns, in particular afucosylation (also referred to as “defucosylation”), mutations (point mutations, deletions, insertions) and fusions with oligo- or polypeptides. Known techniques for altering glycosylation patterns include overexpression of heterologous β1,4-N-acetylglucosaminyltransferase III in the antibody-producing cell (known as the Glycart-Roche technology) and knocking out of the gene encoding α-1,6-fucosyltransferase (FUT8) in the antibody-producing cell (the Potelligent technology from Kyowa Hakko Kirin). Specific examples of enhancing mutations in the Fc part include those described in Shields et al., J. Biol. Chem. 276:6591-6604 (2001), which is incorporated herein in its entirety.
In accordance with the present invention, the bispecific construct is particularly designed in such a way that the killing of IL23R-expressing target cells by Tc cells is highly efficient. Such efficient killing generally involves the ability of the bispecific construct to effectively redirect Tc cells to lyse IL23R-expressing target cells. The term “efficient”, as used herein, means that the bispecific construct of the present invention typically shows an in vitro EC50 ranging from 10 to 500 ng/ml, and is able to induce redirected lysis of about 50% of the target cells through Tc cells at a ratio of Tc cells to target cells of from 1:1 to 50:1, particularly from 1:1 to 15:1, more particularly from 2:1 to 10:1. As used herein above and below, the terms “about” and “approximately” refer to ±10% of the indicated value or range.
Furthermore, the bispecific construct of the present invention is particularly capable of cross-linking a stimulated or an (otherwise) unstimulated Tc cell and the target cell in such a way that the target cell is lysed. This offers the advantage that no generation of target-specific T cell clones or common antigen presentation by dendritic cells is required for the bispecific construct to exert its desired activity. In fact, the bispecific construct of the present invention is particularly capable of redirecting Tc cells to lyse the target cells in the absence of other activating signals. More particularly, if the first binding moiety of the bispecific construct specifically binds to CD3, particularly to CD3ε, signaling through CD28 and/or IL-2 is not required for redirecting Tc cells to lyse the target cells. The high potential to activate non-target specific and/or unstimulated Tc cells is considered to be an important feature of the bispecific construct of the present invention and is believed to contribute to the efficient killing of target cells.
The present invention further contemplates that the first and second binding moieties are particularly arranged relative to each other in such a manner that the bispecific construct preferentially binds to the first antigen present on a Tc cell and, simultaneously, to the second antigen (i.e., IL23R) present on the target cell, but is essentially not capable of simultaneous binding to a single cell that co-expresses both the first antigen and IL23R (e.g. an IL-17 expressing cytotoxic (Tc17) cell).
Methods for measuring the preference of the bispecific construct to simultaneously bind to two cells are within the normal capabilities of a person skilled in the art. For example, the bispecific construct of the present invention may be contacted with a mixture of CD3+/IL23R− cells and CD3+/IL23R+ cells or with a mixture of CD3+/IL23R− cells and CD3+/IL23R+ cells. The number of bispecific construct-positive single cells and the number of cells crosslinked by bispecific constructs may then be assessed by microscopy or fluorescence-activated cell sorting (FACS) as known in the art. About the same number of observed bispecific cross-linked cells in both set-ups indicate that the bispecific construct of the present invention does not, or does essentially not, bind to a single target cell exhibiting both the CD3 and IL23R antigen on its surface. Alternatively, the apparent binding activity avidity may be determined. If simultaneous binding to a single target cell is not, or is essentially not, possible, the apparent binding activity of the bispecific construct for IL23R+/CD3− or IL23R+/ CD3+ cells on one side and IL23R+/CD3+ cells on the other side will be about the same. If, however, simultaneous binding to a single target cell is possible, the apparent binding activity of the bispecific construct for IL23R+/CD3+cells will be higher than that for IL23R+/CD3- or IL23R7CD3+cells due to avidity effects.
In a particular embodiment of the present invention, the bispecific construct has a structure where the first and second binding moieties are arranged relative to each other in such a manner that the part of the first binding moiety recognizing the first antigen and the part of the second binding moiety recognizing the second antigen project, relative to the center of the bispecific construct, outward in essentially opposite directions. The term “center” particularly relates to the center of geometry (COG). Without being bound by any theory, it is believed that this structure of the bispecific construct of the present invention avoids the undesired double-binding to a single target cell as outlined above. The term “essentially”, as used in the present context, means that said part of the first binding moiety and said part of the second moiety are arranged, relative to the center of the bispecific construct, at an angle of 135° or more up to 180°.
The structure of the bispecific construct is particularly also characterized in that the angle a between a first vector v1 from the center of geometry (COG) of the entire bispecific construct to the COG of the first paratope of the first binding moiety and a second vector v2 from the COG of the entire bispecific construct to the COG of the second paratope of the second binding moiety is approximately within the range of 135°<α<180°, more particularly within the range of 150°<α<180°, and most particularly within the range of 160°<α<180°. The term “paratope”, as used herein, refers to the portions of the first and second binding moieties that directly interact with the first and second antigens, respectively.
In the context of the present invention, the first binding moiety and/or the second binding moiety is an antibody-based binding moiety, particularly an antibody-based binding moiety comprising a heavy chain variable domain (VH) or binding fragment thereof, more particularly an antibody-based binding moiety comprising a heavy chain variable domain (VH) or binding fragment thereof and a light chain variable domain (VL) or binding fragment thereof. The term “binding fragment”, as used herein, refers to a portion of a given domain, region or part, which is (either alone or in combination with another domain, region or part thereof) still functional, i.e. capable of binding to the first or second antigen recognized by the bispecific construct.
Typically, a binding fragment within the meaning of the present invention retains at least 10% of its native antigen binding activity (i.e. of its antigen binding activity as a monospecific construct) when comprised in a bispecific construct of the present invention. Particularly, a binding fragment retains at least 25%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of its native antigen binding activity, or maintains or even exceeds the full native antigen binding activity, although any binding fragment with sufficient affinity to exert the desired biological effect (i.e. lysing/killing of target cells by Tc cells) will be useful. It is also intended that a “binding fragment” within the meaning of the present invention includes variants having conservative amino acid substitutions that retain their binding activity to the extent defined above and, particularly, do not substantially alter their binding or biological activity.
In another particular embodiment of the present invention, the bispecific construct is an antibody format selected from the group consisting of a single-chain diabody (scDb), a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a circular dimeric scDb (CD-scDb), a bispecific T-cell engager (BiTE; tandem di-scFv), a tandem tri-scFv, a Tribody, a triabody, bispecific Fab2, di-miniantibody, tetrabody, scFv-Fc-scFv fusion, di-diabody, DVD-Ig, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, such as bsAb (scFv linked to C-terminus of light chain), Bs1Ab (scFv linked to N-terminus of light chain), Bs2Ab (scFv linked to N-terminus of heavy chain), Bs3Ab (scFv linked to C-terminus of heavy chain), Ts1Ab (scFv linked to N-terminus of both heavy chain and light chain), Ts2Ab (dsscFv linked to C-terminus of heavy chain), and Knob-into-Holes (KiHs) (bispecific IgGs prepared by the KiH technology) and DuoBodies (bispecific IgGs prepared by the Duobody technology). Particularly suitable for use herein is a single-chain diabody (scDb), in particular a bispecific monomeric scDb.
The bispecific scDb, in particular the bispecific monomeric scDb, particularly comprises two variable heavy chain domains (VH) or fragments thereof and two variable light chain domains (VL) or fragments thereof connected by linkers L1, L2 and L3 in the order VHA-L1-VLB-L2-VHB-L3-VLA, VHA-L1-VHB-L2-VLB-L3-VLA, VLA-L1-VLB-L2-VHB-L3-VHA, VLA-L1-VHB-L2-VLB-L3-VHA, VHB-L1-VLA-L2-VHA-L3-VLB, VHB-L1-VHA-L2-VLA-L3-VLB, VLB-L1-VLA-L2-VHA-L3-VHB or VLB-L1-VHA-L2-VLA-L3-VHB, wherein the VLA and VHA domains jointly form the antigen binding site for the first antigen, and VLB and VHB jointly form the antigen binding site for IL23R.
The linker L1 particularly is a peptide of 2-10 amino acids, more particularly 3-7 amino acids, and most particularly 5 amino acids, and linker L3 particularly is a peptide of 1-10 amino acids, more particularly 2-7 amino acids, and most particularly 5 amino acids. The middle linker L2 particularly is a peptide of 10-40 amino acids, more particularly 15-30 amino acids, and most particularly 20-25 amino acids.
In a particular embodiment of the present invention, the VH domain of the first and second antibody-based binding moieties of the bispecific construct comprises rabbit heavy chain complementarity determining regions (CDRs) grafted onto human heavy chain framework (FW) regions, and the VL domain of the first and second antibody-based binding moieties of the bispecific construct comprises rabbit light chain CDRs grafted onto human light chain FW regions.
The heavy chain and light chain CDRs of the first antibody-based binding moiety are particularly derived from a rabbit antibody obtained by immunization of a rabbit with the full-length epsilon chain of human CD3 the full-length, CD28 or the full-length C1q. The immunization with the full-length chain of CD3s, CD28 or C1q is suitably conducted by DNA immunization of a rabbit with a plasmid encoding the full-length chain of human CD3e, CD28 or C1 q, or, alternatively, with the purified extracellular domain of the epsilon chain of CD3, or with the purified extracellular chain of CD28, or with the purified C1 q. Further, the heavy chain and light chain CDRs of the second antibody-based binding moiety are particularly derived from a rabbit antibody obtained by immunization of a rabbit either with the purified extracellular domain of IL23R or with a plasmid expressing the full-length IL23R.
The bispecific constructs of the present invention can be produced using any convenient antibody manufacturing method known in the art (see, e.g., Fischer, N. & Leger, O., Pathobiology 74:3-14 (2007) with regard to the production of bispecific constructs; Hornig, N. & Färber-Schwarz, A., Methods Mol. Biol. 907:713-727, 2012, and WO 99/57150 A2 with regard to bispecific diabodies and tandem scFvs). In addition, exemplary anti-IL23R and anti-CD3ε antibody sequences are disclosed in EP 2 395 025 and EP 1 348 715, respectively. Specific examples of suitable methods for the preparation of the bispecific construct of the present invention further include, inter alia, the Genmab (see Labrijn et al., Proc. Natl. Acad. Sci. USA 110:5145-5150 (2013)) and Merus (see de Kruif et al., Biotechnol. Bioeng. 106:741-750 (2010)) technologies. Methods for production of bispecific antibodies comprising a functional antibody Fc part are also known in the art (see, e.g., Zhu et al., Cancer Lett. 86:127-134 (1994)); and Suresh et al., Methods Enzymol. 121:210-228 (1986)).
These methods typically involve the generation of monoclonal antibodies, for example by means of fusing myeloma cells with the spleen cells from a mouse that has been immunized with the desired antigen using the hybridoma technology (see, e.g., Yokoyama et al., Curr. Protoc. Immunol. Chapter 2, Unit 2.5, 2006) or by means of recombinant antibody engineering (repertoire cloning or phage display/yeast display) (see, e.g., Chames & Baty, FEMS Microbiol. Letters 189:1-8 (2000)), and the combination of the antigen-binding domains or fragments or parts thereof of two different monoclonal antibodies to give a bispecific construct using known molecular cloning techniques.
The bispecific constructs of the present invention are particularly humanized in order to reduce immunogenicity and/or to improve stability. Techniques for humanization of antibodies are well-known in the art. For example, one technique is based on the grafting of complementarity determining regions (CDRs) of a xenogeneic antibody onto the variable light chain VL and variable heavy chain VH of a human acceptor framework (see, e.g., Jones et al., Nature 321:522-525 (1986); and Verhoeyen et al., Science 239:1534-1536 (1988)). In another technique, the framework of a xenogeneic antibody is mutated towards a human framework. In both cases, the retention of the functionality of the antigen-binding portions is essential (Kabat et al., J. Immunol. 147:1709-1719 (1991)).
The bispecific constructs of the present invention may alternatively comprise one or more binding moieties based on non-antibody based binding domains. Specific examples of suitable methods for the preparation of the bispecific construct of the present invention further include, inter alia, the DARPin technology (Molecular Partners AG), the adnexin technology (Adnexus), the anticalin technology (Pieris), and the Fynomer technology (Covagen AG).
In a particular embodiment of the present invention, the bispecific construct is PRO165 (SEQ ID NO: 7), or a functionally active variant of PRO165.
In the context of the present invention, the term “functionally active variant of PRO165” refers to a bispecific construct based on the VL and VH regions of PRO165, wherein (i) said bispecific construct maintains the functional activity of PRO165, i.e. wherein a first VH/VL pair specifically binds to CD3c, and wherein a second VH/VL pair specifically binds to the IL-23 receptor specific subunit (IL23R), and wherein (ii) said VL and VH regions comprise at least one sequence variation compared the VL and VH regions of PRO165. In particular embodiments, the CDR sequences of said functionally active variant are at least 70%, particularly at least 80%, more particularly at least 90% homologous to the CDR sequences of the VL and VH regions of PRO165. Most particularly, the CDR sequences of said functionally active variant are at least 90% identical and at least 95% homologous to the CDR sequences of the VL and VH regions of PRO165. In particular such embodiments, at least the CDR3 regions of the VH regions of said functional variant are identical to the corresponding CDR3 regions of PRO165. In more particular embodiments, all CDR regions of said functional variant are identical to the corresponding CDR regions of PRO165.
In another aspect, the present invention relates to a nucleic acid or multiple (i.e. more than one) nucleic acids encoding the bispecific construct of the present invention. If the bispecific construct is a single-chain construct, e.g. a polypeptide or protein, a single nucleic acid codes for the bispecific construct. However, if the bispecific construct comprises two or more polypeptides, the bispecific construct of the present invention may also be encoded by two or more separate nucleic acids. The nucleic acid molecule(s) according to the invention can be any nucleic acid molecule, particularly a DNA or RNA molecule, for example cDNA or mRNA. They can be naturally occurring molecules or produced through genetic engineering or chemical synthesis. They may be single-stranded molecules, which either contain the coding or the non-coding strand, or double-stranded molecules.
In a particular embodiment of the present invention, said nucleic acid or nucleic acids encode the bispecific construct PRO165 (SEQ ID NO: 7), or a functionally active variant thereof.
The nucleic acid(s) of the present invention may be produced by any suitable method as known to those skilled in the art. The nucleic acids of the present invention can, for example, be synthesized by the phosphoramidite method or the like, or can be produced by polymerase chain reaction (PCR) using specific primers. Furthermore, methods for introducing a desired mutation into certain nucleotide sequence, such as site-directed mutagenesis techniques, are well-known to a person skilled in the art.
In a further aspect, the present invention relates to a vector or multiple vectors comprising the nucleic acid(s) of the present invention. When comprised within a vector, in particular a plasmid, the nucleic acid(s) particularly is (are) DNA. The types of vectors used in the present invention are not particularly limited. For example, the vector may be a vector which replicates autonomously, such as a plasmid, or may be a vector which is integrated into the genome of a host cell when introduced into the host cell and is replicated along with the chromosome. Particularly, the vector used in the present invention is an expression vector, in particular an expression plasmid. In an expression vector, elements necessary for transcription, such as a promoter, are operatively linked to the DNA nucleic acid(s) of the present invention.
Examples of promoters which are operative in bacterial cells include PR or PL promoters of phage lambda, lac, trp or tac promoter of Escherichia coli, and the like. Examples of mammalian promoters include SV40 promoter, MT-1 (metallothionein gene) promoter, adenovirus 2 major late promoter, and the like. Furthermore, exemplary promoters for use in insect cells include polyhedrin promoter, P10 promoter, baculovirus immediate early gene 1 promoter, and the like. Moreover, suitable promoters for yeast host cells include a promoter derived from yeast glycolysis system genes, TPI1 promoter and the like. Other promoters suited for different expression systems are known in the art.
Further, if necessary, the DNA of the present invention may be operatively linked to a suitable terminator, such as a human growth hormone terminator or a TPI1 ADH3 fungal host terminator. The recombinant vector of the present invention may also have an element such as a polyadenylation signal (e.g., derived from SV40), a transcription enhancer sequence (e.g., a SV40 enhancer), or a translation enhancer sequence (e.g., encoding adenovirus VA RNA).
The recombinant vector of the present invention is also typically provided with a DNA sequence which enables the vector to replicate inside the host cell, and an example thereof for mammalian cells is an SV40 origin of replication. Furthermore, the recombinant vector of the present invention may also contain a selectable marker. Examples of a selectable marker include, inter alia, drug resistance genes such as ampicillin, kanamycin, tetracycline, chloramphenicol, neomycin, and hygromycin. Methods for connecting the nucleic acid(s) of the present invention with a promoter and, as desired, other regulatory sequences such as a terminator and/or a secretion signal sequence, and inserting these into a suitable vector are known to those skilled in the art.
In a particular embodiment of the present invention, said vector or vectors comprise a nucleic acid or nucleic acids, which encode(s) the bispecific construct PRO165 (SEQ ID NO: 7), or a functionally active variant thereof.
In yet another aspect, the present invention relates to a host cell or multiple host cells that are not identical, comprising the vector(s) of the present invention. The host cell(s) into which the recombinant vector of the present invention is (are) introduced is (are) not particularly limited and include any prokaryotic or eukaryotic cell which can express the vector of the present invention. Examples of suitable host cells include bacteria (e.g., Bacillus spp., Streptomyces spp., and Escherichia coil), mammalian cells (e.g., HEK293, HeLa, COS, BHK, CHL, and CHO cells), insect cells (e.g., baculovirus expression system), yeast cells (Saccharomyces spp. or Schizosaccharomyces spp., in particular Saccharomyces cerevisae and Saccharomyces kluyveri), and other fungal cells (e.g., Aspergillus, Neurospora). Particularly, the cells are bacterial cells, in particular Escherichia coli cells.
A multiple polypeptide chain bispecific construct can be made in a single host cell expression system wherein the host cell produces each chain of bispecific construct and assembles the polypeptide chains into a multimeric structure to form the bispecific construct, followed by recovery of the bispecific construct from the host cell. Alternatively, the separate polypeptide chains of the desired bispecific construct can be made in separate expression host cells, separately recovered from the respective host cells, and then mixed in vitro under conditions permitting the formation of the multi-subunit bispecific constructs as known in the art.
Methods for introducing the vector of the present invention into suitable host cells are known in the art and include the protoplast method, the competent cell method (for bacterial host cells), electroporation, the phosphate calcium method, lipofection (for mammalian cells or for insect cells/baculovirus system), electroporation, the spheroplast method, and the lithium acetate method (for yeast and other fungal host cells).
In yet a further aspect, the present invention relates to a method for producing the bispecific construct of the present invention, comprising providing a host cell or host cells of the present invention, culturing said host cell or said host cells and collecting the bispecific construct from the cell culture. In the culturing step, the host cell(s) of the present invention is (are) cultured in a suitable culture medium under conditions permitting expression of the bispecific construct of the present invention. The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Alternatively, the present invention relates to a method for producing the bispecific construct of the present invention, comprising providing a nucleic acid or nucleic acids according to the present invention, or a vector or vectors according to the present invention, expressing said nucleic acid or nucleic acids or said vector or vectors, particularly in an in vitro transcription/translation system (see, for example, Yin et al., Mabs 2012 Mar. 1;4(2) 217-25), and collecting said bispecific construct from the expression system.
In the step of collecting the bispecific construct from the cell culture, the produced bispecific construct is recovered by conventional methods for isolating and purifying a protein, including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, and purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography or the like. In a case where the bispecific complex forms insoluble inclusion bodies, for example when using E. coli as host cell, the inclusion bodies may be first solubilized in denaturant, followed by a refolding step in accordance with procedures well known in the art.
In still another aspect, the present invention relates to a pharmaceutical composition comprising the bispecific construct of the present invention and a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable” refers to those compounds or substances which are, within the scope of sound medical judgment, suitable for contact with the tissues of mammals, especially humans, without excessive toxicity, irritation, allergic response and other problem complications. The term “carrier”, as used herein, relates to a diluent, adjuvant, excipient or vehicle whereby the active ingredient is administered. Pharmaceutically acceptable carriers for use herein can be, for example, sterile liquids or dispersions. Particular carriers are those suited for intravenous, subcutaneous or topical administration, including sterile aqueous and non-aqueous solutions or suspensions for parenteral administration, as discussed in Remington: The Science and Practice of Pharmacy, 20th Edition (2000).
The pharmaceutical composition generally includes an effective amount of the bispecific construct of the present invention. Within the present invention, the term “effective amount”, with respect to the pharmaceutical composition or otherwise, refers to the amount of a compound sufficient to effect beneficial or desired therapeutic or prophylactic results. Furthermore, as used herein, the term “treatment” includes both therapeutic and prophylactic treatment and includes both in vivo and ex vivo treatment. A therapeutically effective or prophylactically effective treatment amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. Also, the pharmaceutical composition may include one or more additional active substances that are co-administered with the bispecific construct of the present invention. In addition, the pharmaceutical composition may contain additional pharmaceutically acceptable substances, for example pharmaceutical acceptable excipients such as solubilizing agents, surfactants, tonicity modifiers and the like. As used herein, the term “disease” also includes disorders and conditions.
Additionally, the embodiments herein directed to the treatment of cancer, include treatment of cancer tumors and the treatment of cancer metastasis.
Furthermore, the dosage form of the pharmaceutical composition of the present invention is not particularly limited but particularly is a parenteral formulation, such as an aqueous or non-aqueous solution or dispersion for injection or infusion, or a formulation suited for topical administration. Another particular dosage form is a formulation containing the bispecific construct of the present invention formulated in a controlled or sustained or delayed release matrix. Further, the pharmaceutical composition may also be contained in an implantable device that releases the bispecific construct over time. As used herein, the unit “mcg” refers to micrograms.
In still a further aspect, the present invention relates to the use of the bispecific construct of the present invention in the treatment of an inflammatory and/or autoimmune disease. In particular, the present invention relates to a method for the treatment of an inflammatory and/or autoimmune disease, comprising administering to a subject, for example, a mammalian subject and particularly a human patient, an effective amount of the bispecific construct of the present invention. The meaning of the term “effective amount” is as defined herein above. Typically, an effective amount of the bispecific construct of the present invention is administered in form of the above-described pharmaceutical composition. Suitable administration routes include, but are not limited to, topical and parenteral administration, in particular inhalation, subcutaneous injection, intravenous injection, and injection into the cerebrospinal fluid. The administration regimen is not particularly limited and includes, for example, bi-weekly, monthly, once every other month, once every third, sixth or ninth month and once-a-year or single application administration schemes.
The inflammatory and/or autoimmune disease may be rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, juvenile diabetes, autoimmune uveitis, and multiple sclerosis, Parkinson's disease, Alzheimer's disease, and ischemia-reperfusion injury.
EXAMPLES Example 1 Cloning of Bispecific Antibody ConstructA bispecific construct VHA-L1-VLB-L2-VHB-L3-VLA (wherein the VLA and VHA domains jointly form the antigen binding site for CD3e, and VLB and VHB jointly form the antigen binding site for IL23R) can be assembled by cloning VLA and VHA from the humanized anti- CD3s antibody domain comprised in antibody bscCDl9xCD3 (see EP 1 348 715 A2,
The data available in the public domain suggest that IL23R may be upregulated in certain tumors. However, the available information is not sufficient to validate IL23R as a suitable marker to target cancer cells by a bispecific anti-IL23RxCD3ε antibody format, as neither the absolute expression level, nor the specificity of expression nor the penetrance of IL23R upregulation across different tumor samples are known. To further study the suitability of IL23R as a label for the targeted lysis of tumor cells, we assessed the expression level of IL23R both, on collection of primary cancer tissues, as well as on a broad spectrum of tumor cell-lines. Surprisingly, IL23R mRNA expression levels were elevated in most primary tissue samples from colorectal cancers. Similarly, elevated IL23R mRNA expression was found in all 129 CRC cell-lines studied. In agreement with these findings, IL23R was highly upregulated in all six colorectal cancer cell-lines studied as well as on the A549 lung adenocarcinoma cell-line also on a protein level as assessed by flow-cytometry (
A total of 475 monoclonal B-cells producing antibodies specifically binding to interleukin-23 receptor were isolated from immunized rabbits using flow-cytometry-based single-cell sorting, the principles of which are well known to the expert and are for example described by Lalor et al Eur J Immuno1.1992;22.3001-2011. Monoclonal B cell culture supernatants were first subjected to ELISA screening for binding to human IL23R ECD. In a second step, cross-reactivity to IL23R from mouse and cynomolgus monkey was assessed. Further, the affinity to human and cynomolgus IL23R was assessed using the surface plasmon resonance (SPR) technology (Table 2). The median equilibrium dissociation constant (KD) of those 475 monoclonal antibodies to human IL23R was 6.3E-11M. Five percent of these antibodies bound with an estimated KD below 4.3E-13M. A total of 92 clones selected either for their high affinity or their cross-reactivity to cynomolgus and/or mouse, were subjected to PCR amplification and sequencing of their variable domains.
[000141] The sequencing of the obtained rabbit IgG clones resulted in 68 complete sets of light and heavy chain variable domains (VL and VH). These sets of rabbit variable domains were analyzed by sequence alignment to identify unique clones and to group the sequences into clusters based on sequence homology. This alignment of the VL and VH domains was performed based on the joint amino acid sequences of both domains. The analysis led to the identification of 58 unique clones. In addition to the alignment of the variable domains, the set of sequences of the six complementarity determining regions (CDRs) of each rabbit IgG clone were compared between different clones to identify unique sets of CDRs. In total 58 unique sets of rabbit CDRs, corresponding to 58 independent clones, were identified. These 58 CDR sets were aligned using the multiple alignment tool COBALT and a phylogenetic tree was generated with the Neighbor Joining algorithm as shown in
Following the selection of the clones (described above) rabbit antibodies were expressed and purified for further characterization. The cloning of the corresponding light and heavy chain variable domains entailed the in-vitro ligation of the DNA fragments into a suitable mammalian expression vector. These expression vectors contained consensus sequences for the constant domains of the rabbit IgG light and heavy chains to allow for the assembly and secretion of fully functional rabbit monoclonal IgGs upon co-expression. Subsequent to the vector construction the sequence of the resulting constructs was confirmed again and the plasmid DNA was amplified and purified for mammalian cell transfections. The expression vectors for the rabbit antibody heavy and light chains were transfected into a mammalian suspension cell line for transient heterologous expression by a lipid-based transfection reagent. The conditions like the ratio of heavy to light chain vector were optimized for robust expression levels of secreted monoclonal IgG. The expression culture was cultivated for 7 days in a shaking incubator. At the end of the heterologous expression period the cell culture supernatant was harvested by centrifugation and decanting. Subsequently the secreted rabbit IgGs were affinity purified by Protein A beads. The IgG loaded beads were washed and the purified antibodies were eluted by a pH shift. The elution fractions were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), UV absorbance at 280 nm and size-exclusion high performance liquid chromatography (SE-HPLC) to verify identity, content and purity.
Example 5 Characterization of Purified Monoclonal Rabbit Anti-IL23R AntibodiesThe affinity of the 23 purified rabbit monoclonal antibodies towards IL23R from human, cynomolgus monkey and mouse origin was determined by SPR measurements. The respective results are given in Table 2 below:
The humanization of rabbit antibody clone 14-11-D07 comprised the transfer of the rabbit CDRs onto Numab's proprietary scFv acceptor framework of the VK1/VH3 type. In this process the amino acid sequence of the six CDR regions was identified on the rabbit antibody donor sequence as described elsewhere (Borras, L. et al. 2010. JBC;285:9054-9066) and grafted into the Numab acceptor scaffold sequence. Two variants were generated, where the variant sc01 resulted from exclusively engrafting complementarity determining regions (CDRs) onto the human acceptor variable domain scaffold, while variant sc02 contains further mutations also in the human framework sequence. The two resulting humanized scFvs were characterized for their binding affinity towards IL23R from human, cynomolgus and mouse origin (see Table 3). As no significant difference in affinity was detectable for the two variants, 14-11-D07-sc01 was chosen to be engineered in the scDb format because in this variant no rabbit amino acids were engrafted from the rabbit donor framework sequences to the human acceptor sequence, thus minimizing the risk to provoke anti-drug immune response in humans following application.
With the aim to redirect CD3E+ T cells to lyse IL23R expressing target cells, a bispecific antibody fragment of the so-called single-chain diabody (scDb) format was engineered. This construct termed PRO165 contains the VH and VL of the anti-IL23R scFv 14-11-D07-sc01 , as well as the VH and VL of a humanized rabbit anti-CD3E antibody (clone 6). The anti-CD3E binding domain was selected a) for its high affinity to human CD3E, b) for its excellent cross-reactivity to CD3E from cynomolgus origin, c) for its outstanding stability and resistance towards aggregation, and d) because this CD3ε binder activates T cells exclusively upon cross-linking—as it may for example occur following binding to target cells—thereby minimizing the risk for potential side-effects due to unspecific activation of T cells.
Affinities of the anti-IL23R and anti-CD3ε binding moieties towards human, cyno and mouse IL23R, and human and mouse CD3ε, respectively were measured by SPR (Table 4).
The midpoint of transition for the thermal unfolding of the tested constructs was determined by Differential Scanning Fluorimetry (DSF), essentially as described by Niesen (Niesen et al., Nat Protoc. 2 (2007) 2212-21). The DSF assay is performed in a qPCR machine (e.g. MX3005p, Agilent Technologies). The samples were diluted in buffer (citrate-phosphate pH 6.4, 0.25 M NaCl) containing a final concentration of 5× SYPRO orange in a total volume of 25 μL. Samples were measured in duplicate and a temperature ramp from 25-96° C. programmed. The fluorescence signal was acquired and the raw data was analyzed with the GraphPad Prism (GraphPad Software Inc.; results see Table 5).
To study potency of the scDbs to induce specific lysis of target cells, IL23R expressing cells were co-cultivated with human CD8+ T cells in presence of increasing concentrations of the respective scDb. Lysis of cells in dependence of the scDb concentration was assessed by measuring fluorescence intensity of celltox-green intercalated into DNA. The EC50 of PRO165 for the respective cell-line is given in Table 6.
For the detection of IL23R on the cell membrane, living cells were stained with 5 μg/mL of a biotinylated polyclonal goat anti-IL23R antibody (R&D Systems, Cat. No.BAF1400). As background control, a polyclonal goat IgG isotype was used (R&D Systems, Cat. No.BAF108). Binding of goat polyclonal antibodies to cells was in turn detected by a Phycoerythrin-(PE)-labeled streptavidin (Southern Biotech, Cat. No. 7100-09S). PE fluorescence intensity of stained cells was measured by flow-cytometry (FACS aria III, Becton Dickinson). In order to quantify IL23R molecules per cell anti-human IgG Quantum™ Simply Cellular® (QSC) microspheres (Bangs Laboratories, Cat. No. 816) loaded with human IL-23R Fc chimera (R&D Systems, Cat. No.1400-IR-050) were used as a reference standard. The mean fluorescence intensity (MFI), reflecting the signal intensity at the geometric mean, was measured for both, the goat IgG isotype control as well as for the goat anti-IL23 R antibody. The difference between the MFI of the specific antibody and isotype control antibody (AMFI) was calculated. The normalized MFI was calculated by dividing the MFI obtained with the anti-IL23R antibody by the MFI of the idiotype control. To quantify IL23R molecules on the cell surface the specific Antibody Binding Capacity (ABC) of cells was calculated by regression of the respective MFI to the standard curve generated by use of Quantum™ Simply Cellular® (QSC) microspheres. Calculations were performed in the lot-specific QuickCal® template. To compare unspecific binding the ABC value of cells stained with negative control antibody were subtracted from ABC value of cells stained with the specific antibody.
2. SPR Assay for Determination of Binding Kinetics and Species Cross-Reactivity of Monoclonal Antibodies in Culture SupernatantBinding affinities of monoclonal rabbit anti-IL23R antibodies in sort supernatants were measured by surface plasmon resonance (SPR) using a MASS-1 SPR instrument (Sierra Sensors). For affinity measurements (run in DPBS with 0.05% Tween) an antibody specific for the Fc region of rabbit IgGs (Bethyl Laboratories, Cat. No. A120-111A) was immobilized on a sensor chip (SPR-2 Affinity Sensor, Amine, Sierra Sensors) using a standard amine-coupling procedure. After immobilization, rabbit monoclonal antibodies in culture supernatants were captured by the anti-rabbit IgG antibody while a second immobilized channel served as a control where the capture was replaced by negative supernatant (cultured media that does not contain sorted cells). Human IL23R extracellular domain (ECD) (produced on request by Trenzyme, Germany) at 90 nM was injected into both flow cells for 3 min and dissociation of the protein from the captured IgG on the sensor chip was allowed to proceed for 5 min. In a similar manner the affinities for cynomolgus and mouse IL23R ECD (both at 90 nM, produced on request by Trenzyme) were measured. The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) were calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
3. SPR Assay for Determination of Binding Kinetics and Species Cross-Reactivity of Purified Monoclonal AntibodiesBinding affinities of purified monoclonal rabbit anti-IL23R antibodies were measured in a similar setup as the sort supernatants, except that the sort supernatants were replaced by purified IgGs. A sensor chip (SPR-2 Affinity Sensor, High Capacity Amine, Sierra Sensors) was immobilized by the same procedure, and purified monoclonal antibodies at a concentration of 0.5 μg/ml (diluted in HEPES running buffer: 0.01 M HEPES, 0.15 M NaCl, 0.05% Tween) were captured by the anti-rabbit IgG antibody. No capture was done on the immobilized control channel. Two-fold serial dilutions of human IL23R extracellular domain ranging from 90 to 2.81 nM were injected into the flow cells for 3 min and dissociation of the protein from the captured IgG on the sensor chip was allowed to proceed for 5 min. After each injection cycle, surfaces were regenerated with a single 1 min injection of 10 mM glycine-HCl pH 1.5. In a similar manner the affinities for cynomolgus and mouse IL23R ECD were measured. The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) were calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
4. SPR Assay for Determination of Binding Kinetics and Species Cross-Reactivity of Anti-IL23R scFvs
Binding affinities of anti-IL23R scFvs were measured by surface plasmon resonance (SPR) using a MASS-1 SPR instrument (Sierra Sensors). For affinity measurements (done in HEPES running buffer: 0.01 M HEPES, 0.15 M NaCl, 0.05% Tween) an antibody specific for the Fc region of human IgGs (Bethyl Laboratories, Cat. No. A80-104A) was immobilized on a sensor chip (SPR-2 Affinity Sensor, High Capacity Amine, Sierra Sensors) using a standard amine-coupling procedure. After immobilization, 1 ug/ml recombinant human IL23R Fc chimera (R&D Systems, Cat. No. 1400-IR-050) was captured by the anti-human IgG antibody while a second immobilized channel served as a control where the capture was replaced by buffer. Two-fold serial dilutions of human scFvs ranging from 180 to 2.81 nM were injected into both flow cells for 3 min and dissociation of the scFvs from the chimera on the sensor chip was allowed to proceed for 700 sec. After each injection cycle, surfaces were regenerated with two 1 min injections of 10 mM glycine-HCI pH 1.5. In a similar manner the affinities for cynomolgus and mouse IL23R Fc chimera (R&D Systems, Cat. No. 1686-MR-050) was measured. The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) were calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
5. SPR Assay for Determination of Binding Kinetics and Species Cross-Reactivity of Anti-CD3×IL23R scDbs
Binding affinities of anti-CD3×IL23R scDbs were measured by surface plasmon resonance (SPR) using a MASS-1 SPR instrument (Sierra Sensors). For affinity measurements (done in HEPES running buffer: 0.01 M HEPES, 0.15 M NaCl, 0.05% Tween) to CD3, human heterodimeric single-chain CD3γδ extracellular domain (produced in-house) was immobilized on a sensor chip (SPR-2 Affinity Sensor High Capacity Amine, Sierra Sensors) using a standard amine-coupling procedure. Three-fold serial dilutions of scDbs ranging from 90 to 0.123 nM were injected into the flow cells for 3 min and dissociation of the protein from the immobilized CD3γδ on the sensor chip was allowed to proceed for 700 sec. After each injection cycle, surfaces were regenerated with a 1 min injection of 10 mM Glycine-HCl pH 2.0. In a similar manner the binding to cynomolgus CD3γδ (produced in-house) and mouse CD36E (Sino Biologicals Inc., Cat. No. CT033-M2508H) was measured.
[000154] For affinity measurements to IL23R, human IL23R extracellular domain (produced on request by Trenzyme) was immobilized on a sensor chip (SPR-2 Affinity Sensor High Capacity Amine, Sierra Sensors) using a standard amine-coupling procedure. Two-fold serial dilutions of scDbs ranging from 90 to 5.6 nM were injected into the flow cells for 3 min and dissociation of the protein from the immobilized IL23R on the sensor chip was allowed to proceed for 720 sec. After each injection cycle, surfaces were regenerated with a 1 min injection of 10 mM Glycine-HCl pH 2.0. The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) are calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
6. scDb Mediated Lysis of IL-23R Expressing Cells by Cytotoxic T Cells
For the assessment of the potential of bispecific anti-CD3×IL-23R scDbs to induce target cell lysis human IL-23R expressing cell lines were used. Colon carcinoma DLD-1 or SW480, and erythroleukemia TF-1 were used as target cell lines Unstimulated human CD8+ T-cells isolated as described above were used as effector cells. Target cells were labeled with cell tox green dye (Promega) according to the manufacturer's instructions. Cell lysis was monitored by the CellTox™ green cytotoxicity assay (Promega). The assay measures changes in membrane integrity that occur as a result of cell death. The assay uses an asymmetric cyanine dye that is excluded from viable cells but preferentially stains the dead cell DNA. When the dye binds DNA in compromised cells, its fluorescence properties are substantially enhanced. Viable cells produce no appreciable increases in fluorescence. Therefore, the fluorescence signal produced by the binding interaction with dead cell DNA is proportional to cytotoxicity. Similarly as described above, labeled IL-23R cells (5′000 cells/well) were incubated with CD8+ cytotoxic T-cells at an effector:target ratio of 40:1 in presence of 3-fold serially diluted scDbs (starting concentration 180 nM) in 96 well microtiter plates. To assess unspecific lysis of cells that do not express the target, T-cells were co-incubated with labeled wild-type CHO cells. Fluorescence intensity was analyzed after 48 h of incubation using a multi-mode microplate reader (FlexStation 3, Molecular Devices). Data were analyzed using a four-parameter logistic curve fit using the SoftMax Pro data analysis Software (Molecular Devices), and the molar concentration of scDb required to induce half maximal target cell lysis (EC50) was derived from dose-response curves.
In order to specifically track the fate of target cells, target cells were stained with CellVue® Claret Far Red Fluorescent (Sigma-Aldrich, Cat.No.MINCLARET-1 KT) in a concentration of 5nM Dye according to the manufacturer's instructions. Apoptosis/necrosis was monitored using the Annexin V Apoptosis Detection Kit FITC (eBioscience, Cat.No.88-8005-74) according to the manufacturer's instructions (concentration of dyes: 100 μL/mL Annexin V and 2 μg/mL Propidium iodide). Stained IL-23R cells (5′000 cells/well) were incubated with CD8+ cytotoxic T-cells at an effector:target ratio of 40:1 in presence of serially diluted scDbs (starting concentration 180 nM) in 96 well microtiter plates. To assess unspecific lysis of cells that do not express the target, T-cells were co-incubated with labeled CHO cells. Fluorescence intensities were analyzed after 48 h of incubation using a flow cytometer (FACS aria III, Becton Dickinson). Data were analyzed by discriminate target from effector cells using the far red fluorescent dye (CeIIVue® Claret Far Red Fluorescent). Target cells were gated into live cells and early-/late-stage apoptotic, necrotic cells by Annexin V and PI fluorescence. The data obtained were analyzed using a four-parameter logistic curve fit using the SoftMax® Pro data analysis Software (Molecular Devices), and the molar concentration of scDb required to induce half maximal target cell lysis (EC50) was derived from dose-response curves.
7. Construct Design and Manufacturing of scDb Constructs
The single-chain diabody constructs were designed by arranging the variable domains in a VLA-L1-VHB-L2-VLB-L3-VHA configuration. In these constructs the VLA and VHA domains jointly form the binding site for IL23R while the VLB and VHB domains jointly form the binding site for CD3c. The peptide linkers L1-L3 connecting the variable domains are constructed of the glycine/serine repeats. The two short linkers L1 and L3 are composed of a single G4S repeat, whereas the long linker L2 is composed of the sequence (G4S)4. The nucleotide sequences encoding the various anti-IL23R×CDE3c scDb constructs were de novo synthesized and cloned into an adapted vector for E.coli expression that is based on a pET26b(+) backbone (Novagen).
The expression construct was transformed into the E. coli strain BL12 (DE3) (Novagen) and the cells were cultivated in 2YT medium (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual) as a starting culture. Expression cultures were inoculated and incubated in shake flasks at 37° C. and 200 rpm. Once an OD600 nm of 1 was reached protein expression was induced by the addition of IPTG at a final concentration of 0.5 mM. After overnight expression the cells were harvested by centrifugation at 4000 g. For the preparation of inclusion bodies the cell pellet was resuspended in IB Resuspension Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.5% Triton X-100). The cell slurry was supplemented with 1 mM DTT, 0.1 mg/mL Lysozyme, 10 mM Leupeptin, 100 μM PMSF and 1 μM Pepstatin. Cells were lysed by 3 cycles of ultrasonic homogenization while being cooled on ice. Subsequently 0.01 mg/mL DNAse was added and the homogenate was incubated at room temperature for 20 min. The inclusion bodies were sedimented by centrifugation at 15000 g and 4° C. The IBs were resuspended in IB resuspension Buffer and homogenized by sonication before another centrifugation. In total a minimum of 3 washing steps with IB Resuspension Buffer were performed and subsequently 2 washes with IB Wash Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA) were performed to yield the final IBs.
For protein refolding the isolated lBs were resuspended in Solubilization Buffer (100 mM Tris/HCl pH 8.0, 6 M Gdn-HCl, 2 mM EDTA) in a ratio of 5 mL per g of wet IBs. The solubilization mixture was incubated for 30 min at room temperature until DTT was added at a final concentration of 20 mM and the incubation was continued for another 30 min. After the solubilization was completed the solution was cleared by 10 min centrifugation at 21500 g and 4° C. The refolding was performed by rapid dilution at a final protein concentration of 0.3 g/L of the solubilized protein in Refolding Buffer (typically: 100 mM Tris-HCl pH 8.0, 5.0 M Urea, 5 mM Cysteine,1 mM Cystine). The refolding reaction was routinely incubated for a minimum of 14 h. The resulting protein solution was cleared by 10 min centrifugation at 8500 g and 4° C. The refolded protein was purified by affinity chromatography on Capto L resin (GE Healthcare) followed by a size-exclusion chromatography on a Superdex 75 column (GE Healthcare). The proteins were formulated in native buffer (50 mM Citrate-Phosphate pH 6.4, 150 mM NaCl). The isolated monomer fraction was analyzed by size-exclusion HPLC, SDS-PAGE for purity and UV/Vis spectroscopy for protein content.
Example 9 Engineering and Characterization of a Bispecific Single-Chain Diabody Surrogate (scDb)With the aim to redirect murine CD3E+ T cells to lyse IL23R expressing target cells, a bispecific antibody fragment of the single-chain diabody (scDb) format was engineered. This construct termed PRO387 contains the VH and VL of the anti-IL23R scFv 14-11-D07-sc01, as well as the VH and VL of a hamster anti-CD3E antibody (2C11). The mouse reactive 2C11 has been described in the literature (Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374) and has been extensively characterized so that structural and sequence information is available (Fernandes R A, et al. 2012. J.Biol.Chem. 287: 13324-13335).
Affinities of the anti-IL23R and anti-CD3E binding moieties towards mouse IL23R, and mouse CD3E, respectively were measured by SPR (Table 8).
With the aim to redirect murine CD3E+ T cells to lyse IL23R expressing target cells, a bispecific antibody fragment, a Fab-scFv fusion (EP1049787 B1) format, was engineered. This heterodimeric construct termed PRO386 contains the Fab fragment of the mouse reactive 2C11 (VL-CL & VH-CH1), both chains are C-terminally fused to an anti-IL23R scFv 14-11-D07-sc01 via a flexible linker.
In addition to the bispecific molecule a mouse reactive anti-CD3 Fab (PRO400) was constructed devoid of the fused scFv modules.
Affinities of the anti-IL23R and anti-CD3E binding moieties towards mouse IL23R, and mouse CD3E, respectively were measured by SPR (Table 8).
1. Construct Design and Manufacturing of Surrogate scDb Construct
The single-chain diabody construct was designed by arranging the variable domains in a VLA-L1-VHB-L2-VLB-L3-VHA configuration. In these constructs the VLA and VHA domains jointly form the binding site for IL23R while the VLB and VHB domains jointly form the binding site for CD3E. The peptide linkers L1-L3 connecting the variable domains are constructed of the glycine/serine repeats. The two short linkers L1 and L3 are composed of a single G4S repeat, whereas the long linker L2 is composed of the sequence (G4S)4. The nucleotide sequences encoding the anti-IL23R x CDE3E scDb construct was de novo synthesized and cloned into an adapted vector for mammalian expression that is based on a pcDNA3.1 backbone (Invitrogen) with an IL-2 signal sequence preceding the open reading frame. The transient expression of the functional scDb was performed with the FreeStyle™ MAX system in CHO S cells (Invitrogen). After cultivation for several days the supernatant of the expression culture was recovered for purification.
[000166] The protein was purified by affinity chromatography on Capto L resin (GE Healthcare) optionally followed by a size-exclusion chromatography on a Superdex 75 column (GE Healthcare). The proteins were formulated in PBS buffer (Lonza, REF BE17-517Q). The isolated monomer fraction was analyzed by size-exclusion HPLC, SDS-PAGE for purity and UV/Vis spectroscopy for protein content.
2. Construct Design and Manufacturing of Surrogate Fab-scFv Fusion Construct and Anti-mCD3 FabThe heterodimeric Fab-scFv construct was designed by preparing to mammalian expression constructs for a co-transfection in suitable host cells. The configuration of these protein chains are VLA-CL-L4-VLB-L2-VHB and VHA-CH1-L4-VLB-L2-VHB, respectively. In these constructs the domains VLA and VHA correspond to the native amino acid sequence from the 2C11 hamster antibody that have been combined with human CL and CH1 sequences to form a chimeric Fab fragment. The scFv modules VLB-L2-VHB from the anti-IL23R 14-11-D07-sc01 have been fused to the C-terminus of the constant domains via an intermediate linker L4 composed of the sequence (G4S)2. In addition to the bispecific construct also the chimeric Fab fragment of the 2C11 was constructed without the fusion of the scFv modules.
The nucleotide sequences encoding the constructs were de novo synthesized and cloned into an adapted vector for mammalian expression that is based on a pcDNA3.1 backbone (Invitrogen) with an IL-2 signal sequence preceding the open reading frame. The transient expression of the functional scDb was performed with the FreeStyle™ MAX system in CHO S cells (Invitrogen). After cultivation for several days the supernatant of the expression culture was recovered for purification.
The protein was purified by affinity chromatography on Kappa Select resin (GE Healthcare) optionally followed by a size-exclusion chromatography on a Superdex 75 column (GE Healthcare). The proteins were formulated in PBS buffer (Lonza, REF BE17-517Q). The isolated monomer fraction was analyzed by size-exclusion HPLC, SDS-PAGE for purity and UV/Vis spectroscopy for protein content.
This example was performed in wild-type C57B/6 mice in accordance with an IMQ induced psoriasis disease model. The mouse back was shaved, and a daily dose of 50 mg of Aldara (5% IMQ cream; 3M Pharmaceuticals) was applied on the back of each mouse for 5 days. Antibody treatment was performed by daily intraperitoneal injection with 0.4, 2, 10, or 50 mcg/mouse of the bispecific anti-IL23RxCD3 antibody fragments (PRO386 and PRO387) or PBS as a control with n=3 per dose group. Injections started two days prior to first Aldara application on study day −1, and were repeated daily until day 4. Cell preparation: Skin was cut into small pieces and digested with 1 mg/ml collagenase type IA and 100 mg/ml DNase (Sigma-Aldrich) for 60 minutes at 37° C. Isolation of leukocytes from the lymph nodes (LN) involved teasing the organs apart. Both were followed by filtering through 70-mcm cell strainers to obtain single-cell suspensions. Antibodies: Cells were incubated with antibodies for 20 minutes at 4° C. For intracellular cytokine staining, cells were stimulated with PMA (Applichem) and ionomycin (Invitrogen) and treated with GolgiStop (BD) for 3 hours. After surface staining, cells were permeabilized according to the manufacturer's (BD) recommendations and stained intracellularly. Stainings were analyzed with a FACS LSRII Fortessa (BD). Post-acquisition analysis was performed with FlowJo (Tree Star) software.
Intraperitoneal injection of the bispecific anti-IL23RxCD3 antibody constructs PRO386 and PRO387 inhibited skin thickening in a dose-dependent manner and blocked clinical symptoms nearly completely at the highest dose of 50 mcg/injection (
This example was performed in IL23R-GFP reporter mice (Awasthi et al, J Immuno.2009;182:5904-5908) in accordance with an IMQ induced psoriasis disease model. The mouse back was shaved, and a daily dose of 50 mg of Aldara (5% IMQ cream; 3M Pharmaceuticals) or control vehicle cream (SoftKreme KA, Kantonsapotheke Zürich) was applied on the back of each mouse for 5 days. Antibody treatment was performed by daily intraperitoneal injection with 50 mcg/mouse of the bispecific anti-IL23RxCD3 antibody fragments (PRO386 and PRO387), the control anti-CD3 Fab fragment, or PBS as a control. Group sizes were n=5 for the PRO386 and PRO387 groups and n=3 for the groups treated with PBS or the anti-CD3 Fab. Injections started two days prior to first Aldara application on study day -1, and were repeated daily until day 4. Cell preparation: Skin was cut into small pieces and digested with 1 mg/ml collagenase type IA and 100 mg/ml DNase (Sigma-Aldrich) for 60 minutes at 37° C. Isolation of leukocytes from the LN involved teasing the organs apart. Both were followed by filtering through 70-mcm cell strainers to obtain single-cell suspensions. Antibodies: Cells were incubated with antibodies for 20 minutes at 4° C. For intracellular cytokine staining, cells were stimulated with PMA (Applichem) and ionomycin (Invitrogen) and treated with GolgiStop (BD) for 3 hours. After surface staining, cells were permeabilized according to the manufacturer's (BD) recommendations and stained intracellularly. Stainings were analyzed with a FACS LSRII Fortessa (BD). Post-acquisition analysis was performed with FlowJo (Tree Star) software.
Intraperitoneal injection of both bispecific anti-IL23RxCD3 antibody constructs PRO386 and PRO387 inhibited skin thickening. The anti-CD3 Fab fragment had no effect. PRO386 blocked clinical symptoms nearly completely at 50 mcg per injection (
An autoimmune encephalomyelitis model (EAE) has been actively induced by peptide immunization as described elsewhere (Miller et al.Curr Protoc Immuno1.2007;Chapter:Unit-15.1.doi :10.1002/0471142735.iml1501s77). Clinical symptoms were assessed on a daily basis using EAE symptom scoring ranging from 0 (no detectable signs of EAE) to 5 (dead). As indicated below, the two bispecific anti-IL23RxCD3 antibody constructs PRO386 and PRO387 were tested in a prophylactic as well a therapeutic setting. Prevention groups were dosed by daily intraperitoneal injection of PRO386 and PRO387 from day 1 after induction until day 8. The therapy groups received daily intraperitoneal injections of 50mcg of PRO386, PRO387 and an anti-CD3 Fab as a control, for 11 days after onset of the disease (score of −0.5).
Disease symptoms, as assessed by EAE scoring peaked at around day 14 for the PBS control group. Both bispecific constructs PRO386 and PRO387 blocked the development of clinical symptoms nearly completely when administered in a prophylactic setting before disease onset (
Mice were injected with B16F10 melanoma cells by the intravenous route and subsequently treated with 50 mcg PRO386 or PBS by daily intraperitoneal injection. After 14 days of treatment, lung metastases were counted for each animal.
ResultsPRO386 significantly reduced the numbers of lung metastasis (
Claims
1. A method for the treatment of a disease selected from the group consisting of: an inflammatory disease, an autoimmune disease and/or cancer, comprising, in a human patient in need thereof, depleting IL23R expressing cells.
2. The method of claim 1, wherein the patient is refractory to treatment via inhibition of IL-1β, IL-6, TGF-β, IL-23, IL-22, IL-17, IL-8, GM-CSF, G-CSF, IFN-γ and/or TNFα signaling.
3. The method of claim 1, wherein said patient has an inflammatory disease and/or an autoimmune disease and is refractory to treatment via inhibition of effector cytokine signaling of IL23R expressing cells and/or cytokine signaling that drives differentiation of IL23R expressing cells.
4. The method of claim 1, wherein the depleting comprises administering to the human patient in need thereof a bispecific construct comprising at least one first binding moiety and at least one second binding moiety, wherein said first binding moiety specifically binds to a first antigen present on a cytotoxic effector cell, and said second binding moiety specifically binds to an IL-23 receptor specific subunit (IL23R) present on the surface of a target cell, wherein said bispecific construct is administered in an effective amount for the treatment of the disease in the patient.
5. The method of claim 4, wherein the cytotoxic effector cell is selected from the group consisting of: a cytotoxic effector T (Tc) cell and a cytotoxic natural killer (NK) cells.
6. The method of claim 4, wherein said first binding moiety specifically binds to an antigen selected from CD3 and CD28.
7. The method of claim 4, wherein said first binding moiety specifically binds to an agonistic epitope of CD3ε.
8. The method of claim 4, wherein said first binding moiety and/or said second binding moiety comprises a heavy chain variable domain (VH) or binding fragment thereof and a light chain variable domain (VL) or binding fragment thereof.
9. The method of claim 4, wherein the bispecific construct is in a format selected from the group consisting of a single-chain diabody (scDb), a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a circular dimeric scDb (CD-scDb), a bispecific T-cell engager (BiTE; tandem di-scFv), a tandem tri-scFv, a tri(a)body, bispecific Fab2, di-miniantibody, tetrabody, scFv-Fc-scFv fusion, di-diabody, DVD-Ig, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, including bsAb, Bs1Ab, Bs2Ab, Bs3Ab, Ts1Ab, Ts2Ab, and Knob-into-Holes (KiHs) and DuoBodies.
10. The method of claim 1, wherein the cancer is cancer metastasis.
11. The method of claim 1, wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, breast cancer, melanoma, brain cancer, nasopharyngeal cancer, oral cancer, esophageal cancer, pancreatic cancer, kidney cancer, B-cell lymphomas, and T-cell lymphomas, including adult T-cell lymphoma leukemia (ATLL), acute myeloid lymphoma (AML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), pediatric acute lymphoblastic lymphoma (B-ALL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), T-/natural killer-cell lymphomas, and peripheral T-cell lymphoma (PTCL).
12. The method of claim 1, wherein the inflammatory and/or autoimmune disease is selected from the group consisting of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, irritable bowel disease, Crohn's disease, systemic lupus erythematosus, juvenile diabetes, autoimmune uveitis, multiple sclerosis, neuromyelitis optica/Devic's disease, Parkinson's disease, Alzheimer's disease, clinically isolated syndrome and ischemia-reperfusion injury.
13. The method of claim 1, wherein the treatment is in an amount to effective to treat recurrence of the inflammatory and/or autoimmune disease.
14. The method of claim 3, wherein the effector cytokines are IL-17, IL-22, GM-CSF, G-CSF, TNF and/or IFN-gamma.
15. The method of claim 3, wherein the cytokines that drive differentiation are IL-1 beta, TGF-beta, IL23, IFN-gamma and/or IL-6.
16. The method of claim 7, wherein the IL23R binding moiety VL is: (SEQ ID NO: 3) DIQMTQSPSSLSASVGDRVTITCQASENIYSFLAWYQQKPGKAPKLLIYS ASKLAAGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNRYSNPDIY NVFGQGTKLTVLG; and the IL23R binding moiety VH is: (SEQ ID NO: 4) EVQLVESGGGLVQPGGSLRLSCAASGIDFNSNYYMCWVRQAPGKGLEWIG CIYVGSHVNTYYANWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAT SGSSVLYFKFWGQGTLVTVSS.
17. The method of claim 16, wherein the CD3 binding moiety VL is: (SEQ ID NO: 5) DIQMTQSPSSLSASVGDRVTITCQSSESVYNNKRLSWYQQKPGKAPKLLI YTASSLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQGEFTCSNAD CFTFGQGTKLTVLG; and the CD3 binding moiety VH is: (SEQ ID NO: 6) EVQLVESGGGLVQPGGSLRLSCAASGFPLSSYAMIWVRQAPGKGLEWIGM ILRAGNIYYASWVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARRHY NREGYPIGIGDLWGQGTLVTVSS.
Type: Application
Filed: May 18, 2015
Publication Date: Nov 19, 2015
Inventors: David URECH (Waedenswil), Tea GUNDE (Waedenswil), Sebastian MEYER (Waedenswil)
Application Number: 14/715,398
